ImmunityBio Shares Surge on Clinical and Commercial Milestones

A convergence of robust clinical data, explosive revenue growth, and a key international regulatory approval has propelled ImmunityBio’s stock to dramatic gains this week. The biopharmaceutical company’s recent announcements have ignited investor enthusiasm, raising the central question of whether this rally is built on a foundation sustainable for the long term.

The momentum began earlier in the week with the release of preliminary full-year 2025 figures. ImmunityBio reported preliminary net product revenue for its therapy Anktiva of approximately $113 million. This staggering figure represents growth of roughly 700% year-over-year and exceeded analyst expectations, providing the first clear evidence of the drug’s commercial traction—a critical metric for emerging biotech Read more...